Coverage
Healthcare investment & market access
Payers, formulary committee members, and health economists who can tell you what will actually get reimbursed, and why.
Who sits on the panel
Where this gets used
Payer sentiment reads
Get a directional view on formulary placement and prior-authorization likelihood ahead of a launch or readout.
Investment diligence
Ground a therapeutic-area or diagnostics thesis in real payer and provider adoption dynamics.
Health economic model validation
Pressure-test cost-effectiveness assumptions with the health economists who actually build these models.
Market access strategy
Understand the realistic reimbursement pathway for a novel mechanism or device category.
Boardroom questions this answers
Would a mid-size regional payer actually place this on formulary at launch, or wait for real-world data?
What prior-authorization criteria is a payer medical director realistically going to set for this drug class?
Does this health-economic model's assumed adherence rate hold up against what plan actuaries actually see?
How much price pressure will this indication face once a biosimilar enters the class?
In practice
“A biotech's market access team needed a payer read on a novel mechanism ahead of a Phase 3 readout, without tipping their hand to the wrong audience. We ran a small, tightly-scoped panel of formulary committee members and health economists under guardrails set by the client's own medical affairs team, and delivered a directional payer view months before launch planning would normally allow it.”
Composite example, illustrative only.
How we deliver this
Who this serves